| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6335447 | FERRER INTERNACIONAL | Quinolonecarboxylic acid derivatives or salts thereof |
Nov, 2023
(5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399014 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Dec, 2029
(5 years from now) | |
| US9180200 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Jan, 2032
(7 years from now) | |
Xepi is owned by Ferrer Internacional.
Xepi contains Ozenoxacin.
Xepi has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Xepi are:
- US6335447
Xepi was authorised for market use on 11 December, 2017.
Xepi is available in cream;topical dosage forms.
Xepi can be used as treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes.
Drug patent challenges can be filed against Xepi from 11 December, 2021.
The generics of Xepi are possible to be released after 29 January, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2022 |
Drugs and Companies using OZENOXACIN ingredient
NCE-1 date: 11 December, 2021
Market Authorisation Date: 11 December, 2017
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: CREAM;TOPICAL
XEPI family patents
